Yu Xichun, Patterson Eugene, Kem David C
Endocrinology/Harold Hamm Oklahoma Diabetes Center & Heart Rhythm Institute, University of Oklahoma Health Sciences Center, 1200 Everett Dr, Oklahoma City, OK 73104, United States.
Curr Opin Pharmacol. 2009 Apr;9(2):167-72. doi: 10.1016/j.coph.2008.11.005. Epub 2008 Dec 25.
The ubiquitin-proteasome system (UPS) plays a central role in intracellular protein degradation and regulates many cellular processes, including cell proliferation, inflammation, adaptation to stress, cell death, and the removal of damaged or misfolded proteins. Numerous studies have demonstrated that altered UPS function is involved in the pathogenesis of a wide range of cardiac diseases including hypertrophy and failure, myocardial ischemia, atherosclerosis, and diabetic cardiovascular disease. Impairment of proteasome function is a common feature of cardiac disease; however several studies have also demonstrated increased proteasome activity in models similar but not identical with those having decreased function. Recent studies have shown that use of proteasome inhibitors before or following production of the model of cardiac disease may confer cardioprotection under certain conditions.
泛素-蛋白酶体系统（UPS）在细胞内蛋白质降解中起核心作用，并调节许多细胞过程，包括细胞增殖、炎症、应激适应、细胞死亡以及受损或错误折叠蛋白质的清除。大量研究表明，UPS功能改变参与了多种心脏疾病的发病机制，包括肥大和衰竭、心肌缺血、动脉粥样硬化以及糖尿病性心血管疾病。蛋白酶体功能受损是心脏疾病的一个常见特征；然而，一些研究也表明，在功能降低但相似而非完全相同的模型中，蛋白酶体活性增加。最近的研究表明，在心脏疾病模型建立之前或之后使用蛋白酶体抑制剂在某些情况下可能具有心脏保护作用。
